United TherapeuticsUTHR +3.03%88 ROC (Joel Greenblatt) % is 65.72% as of Mar. 2026, which is 39% below its 10-year median of 107.19. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.81 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 978 Drug Manufacturers companies, United Therapeutics ranks better than 92.74% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. United Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 65.72%.
The historical rank and industry rank for United Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:
UTHR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14.39 Med: 107.19 Max: 207.31
Current: 93.83
During the past 13 years, United Therapeutics's highest ROC (Joel Greenblatt) % was 207.31%. The lowest was -14.39%. And the median was 107.19%.
UTHR's ROC (Joel Greenblatt) % is ranked better than 92.74% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs UTHR: 93.83
United Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 8.40% per year.
United Therapeutics (NAS:UTHR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
United Therapeutics ROC (Joel Greenblatt) % Related Terms
United Therapeutics ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTHR vs VTRS, NBIX, ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's ROC (Joel Greenblatt) % falls into.
United Therapeutics ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 65.72% mean?
United Therapeutics (UTHR) has a ROC (Joel Greenblatt) % of 65.72% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on United Therapeutics and its competitors. This is 39% below median its historical median of 107.19. According to the industry distribution chart, United Therapeutics ranks #71 out of 978 companies in the Drug Manufacturers industry, placing it in the top 7.3%.
Is United Therapeutics' ROC (Joel Greenblatt) % too high?
United Therapeutics' current ROC (Joel Greenblatt) % of 65.72% is 39% below median its 10-year median of 107.19. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. United Therapeutics' value of 65.72% is 474% above this industry median. Based on the distribution chart, United Therapeutics ranks #71 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' ROC (Joel Greenblatt) % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #71 out of 978 companies for ROC (Joel Greenblatt) %. This places United Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.45. United Therapeutics' value of 65.72% is 474% above this benchmark. While the company's 10-year median is 107.19 vs. the industry median of 11.45, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current ROC (Joel Greenblatt) % of 65.72% is 474% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current ROC (Joel Greenblatt) % is 65.72%, which is 39% below median its own 10-year median of 107.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.81, compared to a current price of $563.70 — trading 45.7% above its estimated fair value. The current ROC (Joel Greenblatt) % is 65.72%, which is 39% below median its 10-year median of 107.19 and 474% above the Drug Manufacturers industry median of 11.45. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For United Therapeutics (UTHR), the current ROC (Joel Greenblatt) % is 65.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $563.70 is trading 45.7% above its estimated GF Value™ of $386.81.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
ROC (Joel Greenblatt) %: 65.72% (39% below median its 10-year median of 107.19)
GF Value™: $386.81 vs. price of $563.70 (45.7% above fair value)
Industry Position: 474% above the Drug Manufacturers median (#71 of 978)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
